Immuneering announces Q3 2025 results and updates

Immuneering Corporation announced its financial results for the quarter ended September 30, 2025 and shared operational updates.

Rhea-AI Filing Summary

Immuneering Corporation announced its financial results for the quarter ended September 30, 2025 and shared operational updates. The details are contained in a press release dated November 12, 2025, which is provided as an exhibit and treated as furnished rather than filed under securities laws.

Insights

Equity research analyst

Immuneering released Q3 2025 results and operational updates via a furnished press release.

Immuneering Corporation reported financial results for the quarter ended September 30, 2025 and paired them with operational updates. The numbers and specific business developments are contained in a separate press release incorporated as an exhibit to this report.

Because the press release is designated as furnished, it is not subject to certain liability provisions that apply to filed information. Investors looking for detail on revenue, expenses, pipeline progress, or guidance would need to review the accompanying Exhibit 99.1, which holds the substantive metrics and commentary.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immuneering (IMRX) announce in this 8-K report?

Immuneering announced its financial results for the quarter ended September 30, 2025 and provided operational updates. Detailed figures and commentary are included in a November 12, 2025 press release attached as Exhibit 99.1 to the report.

Which period do Immuneering (IMRX) Q3 2025 results cover?

The results cover Immuneering’s financial performance for the quarter ended September 30, 2025. This time frame captures its third-quarter activity, including revenue, expenses, and other key metrics described in the accompanying Exhibit 99.1 press release.

How did Immuneering (IMRX) provide its Q3 2025 financial details?

Immuneering provided full Q3 2025 financial details through a press release dated November 12, 2025. That release is attached as Exhibit 99.1 and is referenced for all specific figures and operational information about the quarter.

Is Immuneering’s Q3 2025 press release considered filed with the SEC?

The Q3 2025 press release is treated as furnished, not filed, under federal securities laws. This means it is not subject to certain liabilities under Section 18 of the Exchange Act unless specifically incorporated by reference elsewhere.

What exhibits are included with Immuneering (IMRX) Q3 2025 results report?

The report includes Exhibit 99.1, a press release issued November 12, 2025 detailing quarterly results and updates, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document for disclosure and data-tagging purposes.

Who signed Immuneering’s Q3 2025 results report?

The report was signed on behalf of Immuneering by Benjamin J. Zeskind, Ph.D. He is identified as Co‑Founder, President, Chief Executive Officer, Director, and the company’s Principal Executive Officer at the time of the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 04:07 PM Learn about SEC filing dates

0001790340FALSE00017903402025-11-122025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

__________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

__________________________________

Immuneering Corporation

(Exact name of Registrant as Specified in Its Charter)

__________________________________

Delaware			001-40675			26-1976972
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

245 Main St.

Second Floor

Cambridge, MA 02142

(Address of principal executive offices) (Zip Code)

(617) 500-8080

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, par value $0.001 per share

IMRX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 12, 2025, Immuneering Corporation (the “Company”) announced its financial results for the quarter ended September 30, 2025 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

The following exhibits relate to Item 2.02, which shall be deemed to be furnished, and not filed:

Exhibit No.						Description
99.1						Press Release issued on November 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			IMMUNEERING CORPORATION
Date: November 12, 2025			By:			/s/ Benjamin J. Zeskind
						Name: Benjamin J. Zeskind, Ph.D.
						Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)